Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent.
作者： Benjamin Solomon , Paul A Bunn Jr
关键词:
摘要: Pemetrexed is a new generation antifolate anticancer agent that inhibits several folate-dependent enzymes required for production of DNA and RNA intermediates. Early studies showed significant hematologic nonhematologic toxicities with this agent. However it was found many these related to functional folate status could be markedly reduced through routine supplementation folic acid vitamin B(12), without adversely affecting efficacy. Phase III pemetrexed have established clinical role drug as single in the second-line treatment non-small cell lung cancer combination cisplatin frontline unresectable malignant pleural mesothelioma. Clinical trials alone or other chemotherapeutic agents shown considerable activity tumor types including colorectal, pancreatic breast cancer, urothelial tumors.
futuremedicine.com
sci-hub.se 参考文章(69)
R. Thödtmann, T. Sauter, S. Weinknecht, L. Weissbach, J. Blatter, U. Ohnmacht, A.‐R. Hanauske, A phase II trial of pemetrexed in patients with metastatic renal cancer. Investigational New Drugs. ,vol. 21, pp. 353- 358 ,(2003) , 10.1023/A:1025480914273
E A Rayl, K A Shackelford, L L Habeck, V F Patel, L G Mendelsohn, V J Chen, S B Gates, R M Schultz, M Ratnam, J R Bewley, S L Andis, W C MacKellar, D J Soose, B A Moroson, W Kohler, L S Gossett, G P Beardsley, C Shih, LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes Cancer Research. ,vol. 57, pp. 1116- 1123 ,(1997)
Frank V. Fossella, Russell DeVore, Ronald N. Kerr, Jeffrey Crawford, Ronald R. Natale, Frank Dunphy, Leonard Kalman, Vincent Miller, Jin Soo Lee, Melvin Moore, David Gandara, Daniel Karp, Everett Vokes, Mark Kris, Yong Kim, Francis Gamza, Luz Hammershaimb, , Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens Journal of Clinical Oncology. ,vol. 18, pp. 2354- 2362 ,(2000) , 10.1200/JCO.2000.18.12.2354
M J Lind, J Cassidy, A C McDonald, S B Kaye, P A Vasey, J R Woodworth, L Adams, S McCarthy, N P Bailey, J Walling, N Siddiqui, T Abrahams, C J Twelves, A H Calvert, A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clinical Cancer Research. ,vol. 4, pp. 605- 610 ,(1998)
D A Rinaldi, H A Burris, F A Dorr, J R Woodworth, J G Kuhn, J R Eckardt, G Rodriguez, S W Corso, S M Fields, C Langley, Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. Journal of Clinical Oncology. ,vol. 13, pp. 2842- 2850 ,(1995) , 10.1200/JCO.1995.13.11.2842
C. Manegold, U. Gatzemeier, J. von Pawel, R. Pirker, R. Malayeri, J. Blatter, K. Krejcy, Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA™ and cisplatin: A multicenter phase II trial Annals of Oncology. ,vol. 11, pp. 435- 440 ,(2000) , 10.1023/A:1008336931378
R. Thödtmann, H. Depenbrock, H. Dumez, J. Blatter, R. D. Johnson, A. van Oosterom, A.-R. Hanauske, Clinical and Pharmacokinetic Phase I Study of Multitargeted Antifolate (LY231514) in Combination With Cisplatin Journal of Clinical Oncology. ,vol. 17, pp. 3009- 3016 ,(1999) , 10.1200/JCO.1999.17.10.3009
X Pivot, E Raymond, B Laguerre, M Degardin, L Cals, J P Armand, J L Lefebvre, D Gedouin, V Ripoche, L Kayitalire, C Niyikiza, R Johnson, J Latz, M Schneider, Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. British Journal of Cancer. ,vol. 85, pp. 649- 655 ,(2001) , 10.1054/BJOC.2001.2010
Mark A. Socinski, Pemetrexed (Alimta) in small cell lung cancer. Seminars in Oncology. ,vol. 32, ,(2005) , 10.1053/J.SEMINONCOL.2005.02.007
Frances A. Shepherd, Janet Dancey, Andrew Arnold, Alan Neville, James Rusthoven, Robert D. Johnson, Bryn Fisher, Elizabeth Eisenhauer, Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer. ,vol. 92, pp. 595- 600 ,(2001) , 10.1002/1097-0142(20010801)92:3<595::AID-CNCR1359>3.0.CO;2-D